At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Personalized Radiation Therapy Through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT)
In Brief
A Phase 2 clinical trial evaluating Computed Tomography, Fludeoxyglucose F-18, and 6 other interventions for Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 and 2 related conditions. Completed, enrolled 51 participants across 2 sites.
Detailed Summary
This phase II trial studies how well positron emission tomography (PET)/computed tomography (CT) and single positron emission computed tomography (SPECT)/CT imaging works in improving radiation therapy treatment in patients with stage IIB-IIIB non-small cell lung cancer. PET/CT imaging mid-way through treatment may be able to accurately show how well radiation therapy and chemotherapy are working. SPECT/CT imaging may be able to tell which parts of the lung tissue are healthier than others. Based on the result of the imaging, treatment adjustments may be made to the radiation therapy to improve survival and decrease toxicity.
Study Details
Timeline
Interventions
Undergo FDG PET/CT
Undergo Tc-99m MAA or Tc-99m DTPA
Undergo FDG PET/CT
Correlative studies
Undergo FDG PET/CT
Undergo functional avoidance radiation therapy
Undergo Tc-99m MAA or Tc-99m Undergo Tc-99m sulfur colloid SPECT/CT
Undergo Tc-99m MAA SPECT/CT
Undergo Tc-99m sulfur colloid